^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    GZMB elevation

    i
    Other names: GZMB, Granzyme B, T-Cell Serine Protease 1-3E, Cathepsin G-Like 1, Granzyme B (Granzyme 2, Cytotoxic T-Lymphocyte-Associated Serine Esterase 1), Cytotoxic T-Lymphocyte Proteinase 2, Cytotoxic Serine Protease B, Human Lymphocyte Protein, Fragmentin 2, CTSGL1, CTLA1, CSPB, CGL1, SECT, C11, HLP, Cytotoxic T-Lymphocyte-Associated Serine Esterase, Lymphocyte Protease, Fragmentin-2, Granzyme-2, Granzyme 2, CTLA-1, CGL-1, CSP-B, CCPI
    Entrez ID:
    3002
    Related biomarkers:
    Expression
    Mutation
    almost2years
    TAK-243 increases tumor immunogenicity enhancing systemic anti-tumor immune response and tumor regression in combination with immune checkpoint inhibition in a syngeneic model of lymphoma (AACR 2023)
    Furthermore, re-inoculation of subjects that exhibited complete regression of tumor masses with A20 cells showed no growth of new tumors. Taken together, these data suggest that intratumor injection of TAK-243 has potential to act as an in situ vaccine which increases anti-tumor immunogenicity and primes tumors for response to ICIs.
    Combination therapy • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • GZMB (Granzyme B)
    |
    TNFA elevation • GZMB elevation
    |
    TAK-243